IDT Australia (IDT) Short Interest
IDT Australia (ASX:IDT) had 0.11% of shares reported as short positions as of 18 May 2026, representing 449,649 shares. IDT Australia operates in the Pharmaceuticals, Biotechnology & Life Sciences industry. Source: ASIC short position report (T+4 delay).
Source: official ASIC short position report, T+4 delay. Methodology · Disclaimer — not financial advice.
IDT Australia
IDT Australia is a Melbourne-based Contract Development and Manufacturing Organisation (CDMO) with over 50 years of experience. They offer end-to-end services from pre-clinical development to commercial-scale supply, covering active pharmaceutical ingredients (APIs) and finished dosage forms (FDFs). Their cGMP facility supports oral medicines and sterile injectables, serving both local and international markets.
Short position
IDT Australia (ASX:IDT) has 0.11% of its shares on issue reported as short positions as of 18 May 2026, or about 449,649 shares. Over the past 30 days that figure has risen 0.10 percentage points, and over 90 days it has risen 0.10 percentage points. Its highest recorded short interest was 0.21% in June 2023. IDT is classified in the Pharmaceuticals, Biotechnology & Life Sciences industry. All figures come from official ASIC short position reports, published with a four trading-day (T+4) delay.
Weekly context: The 10 most shorted ASX stocks — Week 34, 2026.
Price & short interest
Toggle series, zoom, and compare · ASIC daily, T+4IDT intelligence dossier
Public-source evidence for this company, with industry drill-up links.
- Tax paid and taxable income records
- Government contracts and public money
- Emissions and trade exposure
- Political donations and lobbying links
Short interest history & FAQ
Company
AI-generated research profile of Idt Australia
About
More Pharmaceuticals, Biotechnology & Life Sciences Stocks
Other shorted stocks in this sector
Be the first to discuss IDT
Start a research thread or post the first pulse update